IceCure Medical’s Cryoablation Shows Higher Patient Satisfaction in Japan Study

Icecure Medical ( (ICCM) ) has provided an update.

On March 10, 2025, IceCure Medical announced the results of an independent study conducted at Kameda Medical Center in Japan, which found that breast cancer patients who underwent their ProSense® cryoablation reported significantly higher satisfaction compared to those who had standard breast-conserving therapy. This study, published in Gland Surgery, supports the growing trend towards non-surgical treatment options for breast cancer and is expected to aid IceCure’s partner, Terumo Corporation, in seeking regulatory approval for ProSense® in Japan.

More about Icecure Medical

IceCure Medical, listed on Nasdaq as ICCM, develops and markets advanced cryoablation therapy systems using liquid nitrogen for tumor destruction, focusing primarily on breast, kidney, bone, and lung cancers. Their flagship product, the ProSense® system, offers a minimally invasive alternative to surgical tumor removal and is marketed globally, including in the U.S., Europe, and China.

YTD Price Performance: 9.76%

Average Trading Volume: 402,725

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $76.37M

See more data about ICCM stock on TipRanks’ Stock Analysis page.